{"contentid": 488527, "importid": NaN, "name": "Another coronavirus vaccine trial in children to begin", "introduction": "Maryland, USA-based vaccine specialist Novavax is to commence Phase III trials of its coronavirus vaccine candidate in children aged 12 to 17.", "content": "<p>Maryland, USA-based vaccine specialist Novavax (Nasdaq: NVAX) is to commence Phase III trials of its novel coronavirus vaccine candidate in children aged 12 to 17.</p>\n<p>In a sign of the firm&rsquo;s confidence in the product, the program comes ahead of any regulatory approvals having been secured for NVX-CoV2373, a vaccine which uses a traditional recombinant protein-based approach.</p>\n<p>In January, the company released positive Phase III data which showed vaccine efficacy of 89.3% in trials conducted in the UK.</p>\n<p>In mid-January, the firm initiated a rolling submission with the British medicines regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), and is expected to use the UK-based data to secure an emergency approval in the USA.</p>\n<p>R&amp;D president Gregory Glenn said: \"Through the expansion of our PREVENT-19 clinical trial, we hope to build upon the encouraging safety and efficacy data generated to-date in adults for our vaccine candidate and to play a significant global role in offering vaccination to as many people as possible across age groups to end the suffering caused by the pandemic.&rdquo;</p>\n<h2>Broadening use</h2>\n<p>Bolstered by approvals for vaccines from Moderna (Nasdaq: MRNA), AstraZeneca (LSE: AZN), Pfizer (NYSE: AZN) and others, vaccine coverage in some areas, including the USA and the UK, is increasingly widespread.</p>\n<p>In this context, the need to extend coverage to include unvaccinated groups becomes more pressing, and many vaccine developers are rapidly collecting clinical data to support approvals in children.</p>\n<p>To this end, Novavax will launch an additional arm of its ongoing PREVENT-19 trial, recruiting up to 3,000 adolescents aged 12 to 17 across up to 75 sites in the USA.</p>\n<p>Two-thirds of volunteers will receive intramuscular injections of the vaccine and one-third will receive placebo, with participants being monitored for safety for up to two years following the final dose.</p>\n<p>Meanwhile the first vaccine to be approved, Pfizer and BioNTech&rsquo;s (Nasdaq: BNTX) Comirnaty, appears set to get the green light for use in 12 to 15 year olds in the USA, opening up the US campaign to millions more people.</p>\n<p>Moderna is also anticipating results from its study involving children aged 12 to 17, and will also receive data from a study of children aged six months to 12 years old later in 2021.</p>", "date": "2021-05-04 09:48:00", "meta_title": NaN, "meta_keywords": "vaccine, children, coronavirus, commence, aged, data, Phase, trials, trial, candidate, Novavax, specialist, USA-based, Maryland, Nasdaq, approvals, receive", "meta_description": "Maryland, USA-based vaccine specialist Novavax is to commence Phase III trials of its coronavirus vaccine candidate in children aged 12 to 17.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-04 09:47:36", "updated": "2021-05-04 10:23:55", "access": NaN, "url": "https://www.thepharmaletter.com/article/another-coronavirus-vaccine-trial-in-children-to-commence", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novavax_vaccine_large.jpg", "image2id": "novavax_vaccine_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Public health, Research", "geography_tag": "UK, USA", "company_tag": "BioNTech, Moderna, Novavax, Pfizer", "drug_tag": "Comirnaty, NVX-CoV2373", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-04 09:48:00"}